255 related articles for article (PubMed ID: 37710078)
21. Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience.
Barker J; Girolomoni G; Egeberg A; Goncalves J; Pieper B; Kang T
J Dermatolog Treat; 2020 Dec; 31(8):794-800. PubMed ID: 31094242
[TBL] [Abstract][Full Text] [Related]
22. Clinical monograph for drug formulary review: systemic agents for psoriasis/psoriatic arthritis.
Fisher VS
J Manag Care Pharm; 2005; 11(1):33-55. PubMed ID: 15667232
[TBL] [Abstract][Full Text] [Related]
23. Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?
Baumgart DC; Misery L; Naeyaert S; Taylor PC
Front Pharmacol; 2019; 10():279. PubMed ID: 30983996
[TBL] [Abstract][Full Text] [Related]
24. Brodalumab Seems to Recover Its Therapeutic Efficacy After a Relatively Short "Washout" Period with Anti-TNF Agents: A Successful Pattern for Double-switch Therapy.
Tampouratzi E; Sfaelos K; Talaiporou K; Douvali Τ; Katsantonis J
Acta Dermatovenerol Croat; 2023 Aug; 31(1):48-50. PubMed ID: 37843093
[TBL] [Abstract][Full Text] [Related]
25. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
Dutta B; Huys I; Vulto AG; Simoens S
BioDrugs; 2020 Apr; 34(2):159-170. PubMed ID: 31792843
[TBL] [Abstract][Full Text] [Related]
26. The Value of Indirect Comparisons of Systemic Biologics for Psoriasis: Interpretation of Efficacy Findings.
Augustin M; Schuster C; Mert C; Nast A
Dermatol Ther (Heidelb); 2022 Aug; 12(8):1711-1727. PubMed ID: 35834062
[TBL] [Abstract][Full Text] [Related]
27. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
[TBL] [Abstract][Full Text] [Related]
28. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
[TBL] [Abstract][Full Text] [Related]
29. Considerations for assessing the cost of biologic agents in the treatment of psoriasis.
Rich SJ
J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S38-41. PubMed ID: 15253689
[TBL] [Abstract][Full Text] [Related]
30. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
Crespi-Lofton J; Skelton JB
J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
[TBL] [Abstract][Full Text] [Related]
31. Modification of treatment-sequence model with a customizable number of treatments to better reflect contemporary and future clinical practice in moderate to severe psoriasis.
van de Wetering G; Ignacio T; Dhanda D; Patel V; Zhang Y; Zhuo J
J Med Econ; 2022; 25(1):421-427. PubMed ID: 35297738
[TBL] [Abstract][Full Text] [Related]
32. Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice.
Cohen AD; Wu JJ; Puig L; Chimenti S; Vender R; Rajagopalan M; Romiti R; de la Cruz C; Skov L; Zachariae C; Young HS; Foley P; van der Walt JM; Naldi L; Prens EP; Blauvelt A
Br J Dermatol; 2017 Dec; 177(6):1495-1502. PubMed ID: 28646580
[TBL] [Abstract][Full Text] [Related]
33. Biosimilars: From Extrapolation into Off Label Use.
Zhao S; Nair JR; Moots RJ
Curr Pharm Des; 2017; 23(44):6746-6751. PubMed ID: 29189127
[TBL] [Abstract][Full Text] [Related]
34. An Update Review of Biosimilars of Adalimumab in Psoriasis - Bioequivalence and Interchangeability.
Zhou X; Chen Z; Bi X
Drug Des Devel Ther; 2021; 15():2987-2998. PubMed ID: 34267501
[TBL] [Abstract][Full Text] [Related]
35. Treatment patterns, healthcare resource utilization, and costs in patients with moderate-to-severe psoriasis treated with systemic therapy in Japan: A retrospective claims database study.
Tada Y; Kim H; Spanopoulos D; Habiro K; Tsuritani K; Yamada Y; Mandal A; Zhong Y; Hikichi Y
J Dermatol; 2022 Nov; 49(11):1106-1117. PubMed ID: 35946343
[TBL] [Abstract][Full Text] [Related]
36. A Systematic Review of the Economic and Health-Related Quality of Life Impact of Advanced Therapies Used to Treat Moderate-to-Severe Ulcerative Colitis.
Cichewicz A; Tencer T; Gupte-Singh K; Egodage S; Burnett H; Kumar J
Adv Ther; 2023 May; 40(5):2116-2146. PubMed ID: 37000363
[TBL] [Abstract][Full Text] [Related]
37. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).
Phan DB; Bewley AP; Smith CH; Mackenzie T; Griffiths CEM; Lunt M; Warren RB; Yiu ZZN
Br J Dermatol; 2023 Jul; 189(1):62-70. PubMed ID: 37016153
[TBL] [Abstract][Full Text] [Related]
38. Real-world outcomes following switching from anti-TNF reference products to biosimilars for the treatment of psoriasis.
Ruda RC; Kelly KA; Feldman SR
J Dermatolog Treat; 2023 Dec; 34(1):2140569. PubMed ID: 36305624
[TBL] [Abstract][Full Text] [Related]
39. Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004.
Guenther L; Langley RG; Shear NH; Bissonnette R; Ho V; Lynde C; Murray E; Papp K; Poulin Y; Zip C
J Cutan Med Surg; 2004; 8(5):321-37. PubMed ID: 15868311
[TBL] [Abstract][Full Text] [Related]
40. A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency.
Staidle JP; Dabade TS; Feldman SR
Expert Opin Pharmacother; 2011 Sep; 12(13):2041-54. PubMed ID: 21736530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
